Statins stimulate arachidonic acid release and prostaglandin I\textsubscript{2} production in rat liver cells

Lawrence Levine*

Address: Department of Biochemistry, Brandeis University Waltham, MA 02454, USA

Email: Lawrence Levine* - llevine@brandeis.edu

* Corresponding author

Abstract

Statins inhibit 3-hydroxy-3-methylglutaryl (HMG-CoA) reductase, the rate limiting step in cholesterol synthesis. They are, therefore, used clinically to lower cholesterol and prevent atherosclerosis. Statins have beneficial effects on multiple organ systems. Some of these effects are found in the absence of significant changes in cholesterol levels. Polyunsaturated fatty acids also inhibit HMG-CoA reductase and have many of the same beneficial effects of statins. Four statins (mevastatin, lovastatin, simvastatin and atorvastatin) have been tested in rat liver cells for their effect on arachidonic acid (AA) release and prostaglandin I\textsubscript{2} production induced in the presence of lactacystin and 12-O-tetradecanoylphorbol-13-acetate. Each statin stimulated release of AA and induced prostaglandin I\textsubscript{2} production. Mevalonate, the product of HMG-CoA reductase, did not reduce the stimulation observed in the presence of simvastatin indicating that HMG-CoA reductase activity is not involved. In view of the multiple biologic properties of AA, the AA released as a result of the action of the statins may play a role in some of the pharmacological effects attributed to these drugs.

Background

The statins, by inhibiting HMG-CoA reductase activity, reduce cholesterol and isoprenoid synthesis [1]. They are being used primarily in the prevention of atherosclerosis [2,3]. They have proven to be beneficial in preventing stroke [4] and may increase bone formation [5] and lower the risk of dementia [6]. Some of the benefits in patients with myocardial infarction are independent of cholesterol levels. Statins also inhibit cellular proliferation and induce apoptosis of tumor cells [7]. Essential fatty acids have several properties similar to the statins [8,9] and Das [10] has suggested that "essential fatty acids and their metabolites may serve as second messengers of the actions of statins."

Statins affect prostaglandin (PG) production. Mevastatin or lovastatin, at 25 \textmu M, induce PGI\textsubscript{2} production and cyclooxygenase (COX)-2 in human aorta smooth muscle cells [11]. Mevalonate and geranylgeranyl-pyrophosphate block these stimulations implicating the cholesterol biosynthetic pathway in this up-regulation. However, fluvastatin down-regulates rather than up-regulates COX-2 expression in human umbilical vein endothelial cells [12] and lovastatin reduces PGI\textsubscript{2} production in bovine endothelial cells, human skin fibroblasts and arterial smooth muscle cells [13].

I observed that in rat liver cells, the statins stimulate the release of an essential fatty acid, arachidonic acid (AA) and stimulate production of its metabolite, PGI\textsubscript{2}. These stimulations are independent of HMG-CoA reductase activity as measured by the lack of any suppression by mevalonate.
Results
The release of AA from rat liver cells after 6 h incubation with mevastatin, lovastatin and simvastatin is shown in Fig. 1. An extract of the pharmaceutical product Lipitor® also significantly stimulates AA release (data not shown). The release of AA as a function of time in the presence of 50 μM lovastatin or simvastatin is shown in Fig. 2. Stimulation by lovastatin and simvastatin is observed after as little as 15 min incubation with cells (the time of release with mevastatin was not studied). Preincubation of the cells for 2 h with 1 μM actinomycin did not alter the quantity of AA release stimulated by 6 h incubation with simvastatin [17.0 ± 0.30 % (5) was released in the absence of actinomycin compared to 17.6 ± 0.60 % (5) released in its presence]. These results indicate that transcription is not required. I have shown previously that under these conditions, induced PG production is inhibited [14,15]. Nor does mevalonate, the direct product of HMG-CoA reductase, affect the stimulated release by 50 μM simvastatin (Fig. 3).

PGI₂ production is enhanced in cells incubated with lactacystin in the presence of TPA (Fig. 4). Simvastatin, mevastatin and lovastatin enhance the induced PGI₂ levels (Fig. 4). Even at 70 min the quantity of PGI₂ produced by lactacystin plus TPA increased in the presence of 30 μM simvastatin (Fig. 5). The effect of 96 μM mevalonate on simvastatin's amplification of induced PGI₂ in the presence of lactacystin plus TPA is shown in Fig. 6. Mevalonate does not suppress the stimulated PGI₂ production. Meval-
onate amplifies even further the effect of simvastatin on lactacystin plus TPA induced PGI2 production, suggesting a role for a downstream isoprenoid in the induction pathway (Fig. 6).

**Discussion**

Mevastatin, lovastatin, simvastatin and atorvastatin stimulate the release of AA from rat liver cells. They do so even after preincubation with actinomycin. Mevalonate, the product of HMG-CoA reductase, does not suppress simvastatin's stimulated AA release. Therefore, it appears that neither transcription nor cholesterol biosynthesis is required for this stimulated AA release. HMG-CoA reductase activity also is not required for up-regulation of induced PGI2 production by simvastatin.

AA has a number of important bioactivities. It serves as substrate for cyclooxygenases, lipooxygenases and cytochrome P450 epoxygenases. After additional enzyme reactions the products yield a variety of biologically active prostanoids [16]. AA also activates leukocyte NADPH oxidase [17], activates PPAR receptors [18], affects H+ channel [19], K+ channel [20] and Ca2+ channel activities [21]. It elevates heat shock gene expression [22], induces apoptosis [23] and inhibits Ca2+ induced Ca2+ release [24]. In human embryonic kidney cells it down-regulates sterol regulatory element-binding proteins (SREBPs), especially the SREBP-1a isoform [25]. The release of AA after incubation with sulindac and the stimulation of apoptosis via conversion of sphingomyelin to ceramide [26] is a mechanism proposed to mediate cancer chemoprevention by nonsteroidal anti-inflammatory drugs [26]. I have postulated that, in addition to nonsteroidal anti-inflammatory drugs, the continuous use of other commonly prescribed drugs that release AA is potentially cancer preventative [27].

The major product of PGH2 metabolism by these rat liver cells is PGI2, although 10% or less of the metabolites are PGE2 and PGF2a [28]. In this study, only PGI2 was measured. Although PGI2 synthase is an induced enzyme [29], the increased PGI2 production probably reflects COX ac-

**Figure 2**

Time course of release of AA after incubation with 50 µM lovastatin ( jihadists), 50 µM simvastatin (triangle) and the MEM/BSA controls (square). Analyses were performed on triplicate or duplicate dishes. The average value is recorded.
Figure 3
Effect of 188 µM mevalonate on AA release from rat liver cells incubated 6 h in the presence of 50 µM simvastatin. The analyses were performed on triplicate dishes. The bars show the mean values and brackets the SEM. This experiment was repeated two times with similar results.
Figure 4
Effect of 27 µM simvastatin, 100 µM mevastatin and 50 µM lovastatin on lactacystin plus TPA induced 6-keto-PGF₁α production after 6 h incubation. At the levels tested, simvastatin, mevastatin and lovastatin alone do significantly stimulate basal PGI₂ production, but by < 1 ng/ml. The analyses were performed on triplicate dishes. * Statistically significant vs lactacystin plus TPA (P < 0.05). This experiment was repeated with similar results.
Up-regulation of PGI₂ production is in agreement with the findings of Degreave et al. [11] who showed that mevastatin and lovastatin up-regulate COX activity in human aortic smooth muscle cells. However, while up-regulation in the muscle cell system involves cholesterol biosynthesis, the up-regulation observed in rat liver cells does not. Statins also have been shown to down-regulate COX activity in human umbilical vein endothelial cells [12]. In addition to differences inherent in the type of cells being studied by the various investigators, the apparently contradictory findings may also be due to examination of the cells at different stages of growth. The published studies [11–13] use cells at confluent densities and also may have been in the G₀ stage of growth. The rat liver cells studied in this report were at low density (dividing cells).

Since statins activate at μM concentrations, it is likely that the release of AA and effects on PGI₂ production are reflections of interaction with cell membranes.

**Conclusions**

Statins stimulate AA release from and PGI₂ production in rat liver cells. It is not yet possible to assign a biological consequence to either stimulation. However, in view of the many biological activities of AA, its release could generate the essential fatty acid that is postulated to be a mediator of statin action [10]. Such mediation does not involve cholesterol biosynthesis.

**Materials**

The C-9 rat liver cell line was purchased from the American Type Culture Collection (Manassa, VA, USA).
Figure 6
Effect of 96 µM mevalonate on 6-keto-PGF₁α produced by stimulation with 30 µM simvastatin in the presence of lactacystin plus TPA after a 6 h incubation. Analyses were performed on triplicate dishes. * Statistically significant vs lactacystin plus TPA (P < 0.05) ** Statistically significant vs lactacystin plus TPA and simvastatin (P < 0.05).
cells were maintained in Eagle’s minimum essential medium (MEM) supplemented with 10% fetal bovine serum. The [3H] AA (91.8 Ci/mmol) was from NEN Life Science Products, Inc. (Boston, MA, USA). Mevastatin, Lovastatin, DL-mevalonic acid lactone were from Sigma Chemical Co. (St. Louis, MO, USA). I thank Dr. Gregory R. Mundy, Institute for Drug Development, San Antonio, TX, for the generous supply of simvastatin. For the experiments with atorvastatin, CH3CH2OH and CH3OH extracts of Lipitor® tablets were used.

Methods
On the day prior to experiments, the rat liver cells were treated with 0.25% trypsin-EDTA and, after addition of MEM containing 10% fetal bovine serum, the floating cells were seeded onto 35 mm culture dishes. The plating densities varied from 0.1 to 0.5 × 105 cells/35 mm dish. The freshly seeded cultures were incubated 24 h to allow for cell attachment. After decantation of MEM containing the fetal bovine serum, 1.0 ml fresh MEM containing 10% fetal bovine serum and [3H] AA (0.2 µCi/ml) was added and the cells incubated for another 24 h. The cells were washed 4 times with MEM and incubated for various periods of time with 1.0 ml of different concentrations of each compound in MEM containing 1.0 mg BSA/ml. The culture fluids were then decanted, centrifuged at 2000 g for 10 min, and 200 µl of the supernate counted for radioactivity. Radioactivity recovered in the washes before the 6 h incubation was compared to input radioactivity to calculate the % radioactivity incorporated into the cells [30].

For PG12 production, 1.0 ml of MEM supplemented with 10% fetal bovine serum, void of [3H] AA, was added after the first 24 h incubation. The cells were incubated for another 24 h, washed three times with MEM, then incubated with lactacystin plus TPA and the compounds in MEM containing BSA for various periods of time. The culture fluids were decanted and analyzed for 6-keto-PGF1α, the stable hydrolytic product of PG12, by radioimmunoassay [31].

Presentation of data
The [3H] AA release is presented as a percentage of the radioactivity incorporated by the cells. Three to six culture dishes were used for each experimental point. The data are expressed as mean values ± SEM (number of dishes). The data were statistically evaluated by unpaired Student’s t-test. A P value < 0.05 was considered significant.

Acknowledgements
I thank Hilda B. Gjika for preparation of the manuscript and Dr. Armen Tashjian Jr., Department of Cancer Cell Biology, Harvard School of Public Health, for his continuing interest in these studies.

References
1. Goldstein JL and Brown MS Regulation of the mevalonate pathway. Nature 1990, 343:425-430
2. Bellosta S, Bernini F, Ferri N, Quarato P, Canavesi M, Arnaboldi L, Ferroni F, Pietro L, Poladini R, and Corsini A. Direct vascular effects of HMG-CoA reductase inhibitors. Atherosclerosis 1998, 137(Suppl):S101-109
3. Koch KK Effects of statins on vascular wall: vasomotor function, inflammation, and plaque stability. Cardiovasc Res 2000, 47:648-657
4. Vaughan CJ and Delanty N Neuroprotective properties of statins in cerebral ischemia and stroke. Stroke, 1999, 30:1969-1973
5. Mundy G, Garrett R, Harris S, Chan J, Chen D, Rossini G, Boyce B, Zhao M and Gutierrez G Stimulation of bone formation in vitro by statins. Science 1999, 286:1946-1949
6. Jick H, Zornberg GL, Jick SS, Seshadri S and Drachman DA Statins and the risk of dementia. Lancet 2000, 356:1627-1631
7. Knapp AC, Huang J, Starling G and Kiener PA Inhibitors of HMG-CoA reductase sensitize human smooth muscle cells to Fas ligand and cytokine-induced cell death. Atherosclerosis 2000, 152:217-227
8. Ihara-Watanabe M, Umekawa H, Takahashi T and Furuchi Y Effects of dietary alpha- or gamma-linolenic acid on levels and fatty acid compositions of platelet phospholipids, and activity and mRNA abundance of 3-hydroxy-3-methylglutaryl CoA reductase in rats. Comp Biochem Physiol A Mol Integr Physiol 1999, 122:213-220
9. Proksch E, Feingold KR and Elias PM Epidermal HMG-CoA reductase activity in essential fatty acid deficiency: barrier requirements rather than eicosanoid generation regulate cholesterol synthesis. J Invest Dermatol 1992, 99:216-220
10. Das UN Essential fatty acids as possible mediators of the actions of statins. Prostaglandins Leukot Essent Fatty Acids 2001, 65:37-40
11. Degraeve F, Bolla M, Blaise S, Cremion C, Quere I, Boquet P, Levy-Toledano S, Bertoglio J and Habib A Modulation of COX-2 expression by statins in human aortic smooth muscle cells. Involvement of geranylgeranylated proteins. J Biol Chem 2001, 276:6849-6855
12. Inoue I, Goto S, Mizotani K, Awata T, Matsunaga T, Kawai S, Nakajima T, Hokari S, Komoda T and Katayama S Lipophilic HMG-CoA reductase inhibitor has an anti-inflammatory effect: reduction of mRNAs levels for interleukin-1β, interleukin-6, cyclooxygenase-2, and p22phox by regulation of peroxisome proliferator-activated receptor alpha (PPARα) in primary endothelial cells. Life Sci 2000, 67:863-876
13. Falke P, Mattiasson I, Stavenon L and Hood B Effects of a competitive inhibitor (mevinolin) of 3-hydroxy-3-methylglutaryl coenzyme A reductase on human and bovine endothelial cells, fibroblasts and smooth muscle cells in vitro. Pharmacol Toxicol 1989, 64:173-176
14. Peng SS, Hong SL and Levine I Prostaglandin production by methylcholanthrene-transformed mouse BALB/c3T3. Requirement for protein synthesis. J Biol Chem 1977, 252:1408-1413
15. Levine L Nuclear receptor agonists stimulate release of arachidonic acid from rat liver cells. Prostaglandins Leukot Essent Fatty Acids 2002, 67:453-459
16. Smith WL The eicosanoids and their biochemical mechanisms of action. Biochem J 1989, 259:315-324
17. Dana R, Leto TL, Malech HL and Levy R Essential requirement of cytolic phospholipase A2 for activation of the phagocyte NADPH oxidase. J Biol Chem 1998, 273:4416-4423
18. Kliewer SA, Sundseth SS, Jones SA, Brown PJ, Wissel GB, Koble CS, Devchand P, Wahli W, Willson TM, Lenhard JM and Lehmann JM Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma. Proc Natl Acad Sci U S A 1997, 94:4318-4323
19. Henderson LM, Thomas S, Banting G and Chappell JB The arachidonic acid-excitable, NADPH oxidase-associated H+ channel is contained within the multi-membrane-spanning N-terminal region of gp91phox. Biochem J 1997, 325:701-705
20. Lesage F, Maincret F and Lazardzinski M Cloning and expression of human TRAAK, a polyunsaturated fatty acids-activated and mechano-sensitive K(+) channel. FEBS Lett 2000, 471:137-140
21. Mignen O and Shuttleworth TJ I(ARC), a novel arachidonate-regulated, noncapacitative Ca(2+) entry channel. J Biol Chem 2000, 275:9114-9119
22. Jurwich DA, Sistonen L, Sarge KD and Morimoto RI Arachidonate is a potent modulator of human heat shock gene transcription. Proc Natl Acad Sci U S A 1994, 91:2280-2284
23. Surette ME, Fonteh AN, Bernatchez C and Chilton FH Perturbations in the control of cellular arachidonic acid levels block cell growth and induce apoptosis in HL-60 cells. Carcinogenesis 1999, 20:757-763
24. Siegel G, Sternfeld L, Gonzalez A, Schulz I and Schmid A Arachidonic acid modulates the spatiotemporal characteristics of agonist-evoked -Ca2+ waves in mouse pancreatic acinar cells. J Biol Chem 2001, 276:16986-16991
25. Hannah VC, Ou J, Luong A, Goldstein JL and Brown MS Unsaturated fatty acids down-regulate SREBP isoforms 1a and 1c by two mechanisms in HEK-293 cells. J Biol Chem 2001, 276:4365-4372
26. Chan TA, Morin PJ, Vogelstein B and Kinzler KW Mechanisms underlying nonsteroidal antiinflammatory drug-mediated apoptosis. Proc Natl Acad Sci U S A 1998, 95:681-686
27. Levine I Does the release of arachidonic acid from cells play a role in cancer chemoprevention? FASEB Journal 2003,
28. Rigas A and Levine L Arachidonic acid metabolism by rat liver cells (the C-9 cell line). J Pharmacol Exp Ther 1984, 231:230-235
29. Ulrich V, Brugger R, Lottspeich F and Siegel I Properties of prosta- cycbin synthase in Honn er all. Eicosanoids and other bioactive lipids in cancer, inflammation and radiation injury 1997, 113-119
30. Levine L Stimulated release of arachidonic acid from rat liver cells by celecoxib and indomethacin. Prostaglandins Leukot Essent Fatty Acids 2001, 65:31-35
31. Levine L Measurement of arachidonic acid metabolites by ra- dioimmunoassay. Manual of Clinical Laboratory Immunology (Edited by: Rose NR, Friedman H, fahey JL) Washington DC: American Society for Microbiology 1986, 685-691